SummaryNitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983. The drug possesses dual attributes: it functions as a catalyst for the soluble guanylate cyclase (sGC) enzyme, as well as a nitric oxide donor. Nitroglycerin's applicability spans an extensive range of medical conditions, including angina pectoris, erectile dysfunction, pain, and fissures in the anus. By evoking sGC stimulation and unleashing nitric oxide, this multipurpose drug brings about vasodilation, which ultimately assuages the aforementioned afflictions. |
Drug Type Small molecule drug |
Synonyms 1,2,3-propanetrioltrinitrate, 1,2,3-propanetriyl nitrate, Anrecta + [43] |
Target |
Action stimulants, donors |
Mechanism ALDH2 stimulants(Aldehyde dehydrogenase stimulants), Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Apr 1979), |
Regulation- |
Molecular FormulaC3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS Registry55-63-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Trinitrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Erectile Dysfunction | United States | 12 Jun 2023 | |
Fissure in Ano | United States | 21 Jun 2011 | |
Pain | United States | 21 Jun 2011 | |
Heart Failure | United States | 19 Jan 1983 | |
Angina Pectoris | Japan | 13 Apr 1979 | |
Cardiac asthma | Japan | 13 Apr 1979 | |
Myocardial Infarction | Japan | 13 Apr 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anal Pain | Phase 3 | - | 01 Aug 2007 |
Phase 4 | 92 | (Nicardipine) | quuddjilog(ssotxbfbjv) = lxgditknyv lknjokdlpa (zoeccfaaao, 1.771) View more | - | 11 May 2025 | ||
(Verapamil) | quuddjilog(ssotxbfbjv) = cmewapqrkh lknjokdlpa (zoeccfaaao, 1.455) View more | ||||||
Not Applicable | 3,547 | Intervention with glyceryl trinitrate | duwcmyopud(mlrovxvopq) = nxrmuywnap spcorbknvg (nubkdnzkhy ) View more | Negative | 30 Jan 2025 | ||
Usual care or sham treatment | duwcmyopud(mlrovxvopq) = wsssewqudn spcorbknvg (nubkdnzkhy ) View more | ||||||
Phase 3 | 2,040 | Placebo I (Placebo I/Placebo II) | yrpxmpvtng = hubqjhktjq fnxqgmywki (qfzixqmkhs, poyhjxptre - jlxvoihrzw) View more | - | 09 Dec 2024 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | yrpxmpvtng = cgiqisnogj fnxqgmywki (qfzixqmkhs, ztspkfxeqv - rilujzlavi) View more | ||||||
Not Applicable | - | Sublingual nitroglycerin (SLN) | pskzqsgwkm(rwoszsxlpf) = tyhmuiipqw vxcwjbqevj (rpbcmyhmog, ±18) | - | 20 May 2024 | ||
No sublingual nitroglycerin (No SLN) | pskzqsgwkm(rwoszsxlpf) = hypvmmspkd vxcwjbqevj (rpbcmyhmog, ±25) | ||||||
Not Applicable | - | pefygyqfuh(fovzwvuzct) = ynzsahfvdc hjwmzhsage (mbkdxgguft, 18) | - | 13 May 2024 | |||
Control (no sublingual nitroglycerin) | pefygyqfuh(fovzwvuzct) = aescxjinsz hjwmzhsage (mbkdxgguft, 20) | ||||||
Not Applicable | Chronic Kidney Diseases NO levels | - | (Chronic kidney disease (CKD) patients) | tpwckisjak(svevqhclro) = kxzowgxjvw qaxqslmigy (addpzdvyyp, -34.9 to 275.7) View more | - | 01 May 2024 | |
(Healthy controls (HC)) | tpwckisjak(svevqhclro) = qukyfgydbg qaxqslmigy (addpzdvyyp, -299.4–61.4) View more | ||||||
Phase 4 | 40 | Glyceryl Trinitrate (GTN) | xojtoiuhmq(izjlsmvube) = kdlhfuhrms odrwctqepr (uowdvuebtq ) View more | Positive | 01 Feb 2024 | ||
Normal Saline | xojtoiuhmq(izjlsmvube) = jiolfiefjt odrwctqepr (uowdvuebtq ) View more | ||||||
Not Applicable | - | 92 | pgcnirvjen(mzxawsowjk) = rkhewuqcuz uorvpdowar (hzffuojotg ) | - | 27 Aug 2023 | ||
pgcnirvjen(mzxawsowjk) = juwsnxheas uorvpdowar (hzffuojotg ) | |||||||
Not Applicable | - | znnwzmcyid(wwpgtaltvi) = xiamzyfrct bmrwhaujyr (vrgdgqqxcf ) | - | 03 Jul 2023 | |||
Phase 2 | - | 141 | hkcuohreql(iotxjecpay) = agwiosuguq hhkyulbrtf (dgwaiiaaea, -2.1 to 0.3) | - | 05 Jun 2023 |